Journals / Literatür Eczacılık Bilimleri Dergisi / 2019 / Cilt: 8 - Sayı: 2

Toxicity of 3,4-Methylenedioxy-N-Methylamfetamine

3,4-Metilendioksi-N-Metilamfetamin Toksisitesi

Pages
128–137
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To evaluate its history, psychochemical properties, action mechanism, toxicokinetic & toxicodynamic properties, potential toxicity and up-to-date treatment models with the benefit of potential therapeutical effects of MDMA are reviewed in this present paper.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:3,4-Methylenedioxy-N-methylamphetamine (MDMA, ecstasy) is one of the most widely abused illegal drugs.
📊
Key Findings & Data:It was synthesized and patented for the first time by Merck in 1912, it was made as a precursor in a new synthesis process for hemostatic substances.
💡
Conclusion & Impact:To evaluate its history, psychochemical properties, action mechanism, toxicokinetic & toxicodynamic properties, potential toxicity and up-to-date treatment models with the benefit of potential therapeutical effects of MDMA are reviewed in this present paper.
🔬Design:Review & Systematic Survey
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

3,4-Methylenedioxy-N-methylamphetamine (MDMA, ecstasy) is one of the most widely abused illegal drugs. It was synthesized and patented for the first time by Merck in 1912, it was made as a precursor in a new synthesis process for hemostatic substances. It has become increasingly popular amongst young people due to its empatogen and entactogen properties while liver damage, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events and arrhythmias are possible adverse effects. The synthetic psychostimulant MDMA acts as an indirect serotonin, dopamine, and norepinephrine agonist and affects the serotonin and dopamine systems. In addition to methylamphatemine like effects, MDMA also has mescaline like effects. MDMA increases the release of cortisol, oxytocin, and antidiuretic hormone. It has been used therapeutically as an adjunct to psycotherapy in 1970’s but after becoming very popular as a recreatinoal drug, the number ofresearches about MDMA’s therapeutical potential has decreased till the beginning of 2000’s. Over the past few years, MDMA has risen in prominence as an agent to treat post-traumatic stress disorder, alcohol use disorder, social phobia of autistic adults. With its unique receptors and a relatively well-tolerated drug effects when used clinically, MDMA therapy is ideally suited to allow a patient to face with traumatic memories without being overwhelmed by negative affect. To evaluate its history, psychochemical properties, action mechanism, toxicokinetic & toxicodynamic properties, potential toxicity and up-to-date treatment models with the benefit of potential therapeutical effects of MDMA are reviewed in this present paper.

Özet

3,4-metilendioksi-N-metamfetamin (MDMA, ekstazi) en çok suistimal edilen yasa dışı ilaçlardan biridir. 1912 yılında ilk defa Merck tarafından sentezlenmiş ve patenti alınmış olup, hemostatik bir maddenin üretimi aşamasında bir prekürsör olarak ortaya çıkarılmıştır. Empatojen ve entaktojen özellikleri sebebiyle genç nüfus içerisinde popülerliğinin giderek artmasıyla birlikte; karaciğer hasarı, rabdomiyoliz, serotonin sendromu, çoklu organ yetmezliği, kardiyovasküler olaylar ve aritmiler gibi olası yan etkileri bulunmaktadır. Bir sentetik psikostimülan olan MDMA, indirekt serotonin, dopamin ve norepinefrin agonisti olarak davranmakta, serotonin ve dopamin sistemlerini etkilemektedir. Metamfetamin benzeri etkilerinin yanı sıra MDMA, meskalin benzeri etkiler de taşımaktadır. MDMA kortizol, oksitosin ve antidiüretik hormonlarının salınımlarını artırmaktadır. 1970’li yıllarda psikoterapiye yardımcı madde olarak kullanılmış olsa da uyuşturucu olarak kullanımının yaygınlaşması sebebiyle 2000’li yılların başına kadar MDMA’nın potansiyel tedavi edici etkilerinin bulunmasına dair araştırmaların sayısı azalmıştır. Geçtiğimiz birkaç yıl içinde, MDMA; travma sonrası stres bozukluğu, alkol bağımlılığı ve otizmli erişkinlerin sosyal fobilerinin tedavisinde kullanımının söz konusu olmaya başlamasıyla öne çıkmıştır. Klinikte kullanıldığında, kendine özgü reseptörlere ve nispeten iyi tolere edilebilen ilaç etkilerine sahip olması sebepleriyle, MDMA tedavisi hastanın olumsuz duygularla başa çıkmakta zorlanmadan travmatik anılarla yüzleşmesine izin vermesi açısından ideal bir tedavidir. Bu çalışmada, MDMA hakkında tarihçe, fizikokimyasal özellikler, etki mekanizmaları, kinetik ve dinamik özellikleri ile toksisite potansiyeli ve güncel tedavi modellerinde MDMA’nın yararlı olabilecek tedavi etkilerinin derlenmesi amaçlanmıştır.

🔖

Cite This Article

PAK, Y., BAYDAR, T. (2019). Toxicity of 3,4-Methylenedioxy-N-Methylamfetamine. Literatür Eczacılık Bilimleri Dergisi, Cilt: 8 - Sayı: 2, 128–137. https://ajindex.com/articles/274601

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Pardo-Lozano R, Farré M, Yubero-Lahoz S, O’Mathúna B, Torrens M, Mustata C, et al. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). PLoS One. 2012
  2. 7(10):e47599. [Crossref] [PubMed] [PMC] 2. Benzenhöfer U, Passie T. Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction. 2010
  3. 105(8):1355-61. [Crossref] [PubMed] 3. Karch SB. A historical review of MDMA. Open Forensic Sci J. 2011
  4. 4(1):20-4. [Crossref] 4. United Nations Office on Drugs and Crime. World Drug Report 2009. New York: United Nations
  5. p.306. 5. Michael White C. How MDMA’s pharmacology and pharmacokinetics drive desired effects and harms. J Clin Pharmacol. 2014
  6. 54(3):245- 52. [Crossref] [PubMed] 6. Lora-Tamayo C, Tena T, Rodríguez A, Moreno D, Sancho JR, Enseñat P, et al. The designer drug situation in Ibiza. Forensic Sci Int. 2004
  7. 140(2-3):195-206. [Crossref] [PubMed] 7. Mounteney J, Griffiths P, Bo A, Cunningham A, Matias J, Pirona A. Nine reasons why ecstasy is not quite what it used to be. Int J Drug Policy. 2018
  8. [Crossref] [PubMed] 8. González-Mariño I, Zuccato E, Santos MM, Castiglioni S. Monitoring MDMA metabolites in urban wastewater as novel biomarkers of consumption lez-Mari n. Water Res. 2017
  9. [Crossref] [PubMed] 9. Sun JH,Shen JL, Liang LS,XuXYLuiHB, Zhang CL. Experimental investigation on terahertz spectra of amphetamine type stimulants. Chinese Phys Lett. 2005
  10. 22(12):3176-8. [Crossref] 10. Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs. 1986
  11. 18(4): 291-304. [Crossref] [PubMed] 11. Fonsart J, Menet MC, Declèves X, Galons H, Crété D, Debray M, et al. Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Toxicol Appl Pharmacol. 2008
  12. 230(1):117-25. [Crossref] [PubMed] 12. Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS. MDMA-assisted therapy: a new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry. 2016
  13. [Crossref] [PubMed] 13. de La Torre R, Farré M, Ortuño J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of MDMA ('ecstasy’) in humans. Br J Clin Pharmacol. 2000
  14. 49(2):104- 9. [Crossref] [PubMed] [PMC] 14. Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ. 2001
  15. 165(7):917-28. 15. Liechti ME, Baumann C, Gamma A, Vol